Silk fibroin/polyurethane patch implantation in hyperglycemic rat model
Source abstract
Abstract
Purpose To understand the complication and histopathological characteristics between the Silk Fibroin/Polyurethanes (SF/PU) and the host response, and to unveil the compatibility of the patch in diabetes individuals. Methods Rats were divided into DM and control (CT) groups, and the DM group was induced with streptozotocin. All groups underwent the SF/PU patch implantation in the abdominal aorta, and the implanted patches were evaluated at one, two, three, and four weeks after implantation. Results DM group had more fibrosis formation and a delayed endothelialization compared to the CT group. There was no evidence of chronic inflammation in both DM and CT groups. Conclusions Fibrosis in hyperglycemic individuals could promote the formation of new vascular structures in the implanted patch such as endothelial and vascular smooth muscle cells. In summary, the SF/PU patch was no serious complications when implanted under hyperglycemia, and the patch was suitable to implant in diabetes mellitus.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Silk-based biomaterials and applications · Wound Healing and Treatments · Hemostasis and retained surgical items
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Veterinary Surgery, Rajamangala University of Agriculture and Technology, Chon Buri, Thailand
Department of Pre-clinic and Applied Animal Science, Mahidol University, Nakhon Pathom, Thailand
Department of Veterinary Surgery, Tokyo University of Agriculture and Technology, Tokyo, Japan
References (28)
Show source-provided references
1. 10.1113/JP27084110.1113/JP270841 ↗
2. Hadi HAR · Vasc Health Risk Manag · 2007 · 3 · 853
3. 10.1900/RDS.2013.10.13310.1900/RDS.2013.10.133 ↗
4. 10.1177/147916411350068010.1177/1479164113500680 ↗
5. 10.1016/j.bbadis.2013.08.00610.1016/j.bbadis.2013.08.006 ↗
6. 10.1016/j.athoracsur.2006.06.08510.1016/j.athoracsur.2006.06.085 ↗
7. 10.1016/j.ejcts.2009.02.03810.1016/j.ejcts.2009.02.038 ↗
8. 10.1016/j.addr.2012.09.04310.1016/j.addr.2012.09.043 ↗
9. 10.1126/science.118893610.1126/science.1188936 ↗
10. Sultan MT · Adv Exp Med Biol · 2018
11. 10.1016/j.actbio.2013.07.01310.1016/j.actbio.2013.07.013 ↗
12. 10.1038/pj.2012.11910.1038/pj.2012.119 ↗
13. 10.1080/15476278.2017.134437610.1080/15476278.2017.1344376 ↗
14. 10.1007/s10856-017-5999-z10.1007/s10856-017-5999-z ↗
15. 10.1016/j.addr.2012.03.01610.1016/j.addr.2012.03.016 ↗
16. 10.1038/pj.2017.1610.1038/pj.2017.16 ↗
17. 10.3390/polym1008087410.3390/polym10080874 ↗
18. 10.4049/jimmunol.170022310.4049/jimmunol.1700223 ↗
19. 10.4103/2347-9264.16543810.4103/2347-9264.165438 ↗
20. 10.1016/j.biopha.2018.02.10510.1016/j.biopha.2018.02.105 ↗
21. 10.2337/dc11-s23910.2337/dc11-s239 ↗
22. 10.2337/diabetes.48.10.207410.2337/diabetes.48.10.2074 ↗
23. 10.1371/journal.pone.002336610.1371/journal.pone.0023366 ↗
24. 10.1186/s12865-018-0261-010.1186/s12865-018-0261-0 ↗
25. 10.1007/s10396-020-01021-x10.1007/s10396-020-01021-x ↗
26. 10.1253/jcj.63.98810.1253/jcj.63.988 ↗
27. 10.1159/00021921110.1159/000219211 ↗
28. 10.1016/j.ydbio.2018.01.01810.1016/j.ydbio.2018.01.018 ↗